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Abstract:  Palmitate (PA) is a saturated fatty acid that has been reported to be elevated in 
individuals with metabolic syndromes. The effects of fatty acids on the expression of various 
fatty acid receptors on neuronal cells is unknown, as is the effects of fatty acids on GLUT 
transporters. In this study, Neuro-2a (N2a) cells were treated with either 300μM of bovine serum 
albumin (BSA) or 300μM of palmitate conjugated to BSA (PA) at various time points to 
determine the effect of palmitate on the expression of various fatty acid receptors and GLUT 
transporters. RNA isolation followed by RT-PCR with primers specific to various G- protein 
coupled receptors (GPRs) and GLUT transporters was performed on these treated cells and 
further analyzed with statistical tests. 24 hour treatment with 300μM PA yielded increased 
mRNA expression of GPR41, GPR84, GPR119, GPR120 and GLUT5 when compared to vehicle 
control. In order to determine how GLUT5 may be regulated, N2a cells were treated with 300μM 
BSA along with PKA inhibitor KT5720 or GPR120 agonist GW9508. RNA isolation followed 
by RT-PCR showed that GPR41, GPR119 and GLUT5 expression increased with PKA 
inhibition, and GPR120 expression increased with GPR120 stimulation. These results suggest 
that PKA may play a role in the regulation of GPR41, GPR119 and GLUT5 in neuronal cells 
stimulated with palmitate. 
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 Introduction 
Obesity affects over one-third (36.5%) of the adult population in the United States (CDC 
2017). In 2008, the estimated annual medical cost of obesity in the U.S alone was $147 billion 
dollars (CDC 2017). Many factors facilitate the progression of obesity, such as genetic, 
metabolic, and environmental influences, including the consumption of fat-rich diets (Stein 2004 
and Milanski 2009). People who are obese are at higher risk for serious diseases and health 
conditions such as hypertension, dyslipidemia, coronary heart disease and type 2 diabetes 
mellitus (DM) (CDC 2017).  Dyslipidemia is characterized by an abnormal amount of lipids in 
the blood while type 2 DM is characterized by insulin insensitivity with decreased glucose 
transport into muscle, liver and fat cells (Olokoba 2012).  Conditions such as metabolic disorders 
and obesity have also been reported to be associated with higher plasma levels of free fatty acids 
(Boden 008 and Dresner 1999).  These free fatty acids (FFAs) play multiple roles within the 
body, such as providing energy, acting as cell signaling molecules, and stabilizing membranes 
via palmitoylation and myristoylation (Zbigniew 2013).   
 A family of membrane-transversing proteins called G-protein coupled receptors (GPCRs) 
have been found to bind to various FFAs (Coleman 2017).  These GPRs consist of a 7-
transmembrane helix bundle (7TM) connected by 3 intracellular loops and 3 extracellular loops 
with the N-terminus on the outside and C-terminus on the inside (Wu 2017).  Upon binding of 
the ligand to the N terminus of the GPCR, the heterotrimeric G-proteins associated with GPCRs 
are activated (Wu 2017) (Rosenbaum 2014).  Free fatty acids have been found to bind to GPCRs 
such as GPR41, GPR84 and GPR120 (Nagasaki 2012). GPR41 is a member of the GPR40 
family (also including GPR40, GPR42 and GPR43) shown to be activated by short chain fatty 
acids (Wu 2012). GPR84 has been found to be expressed in bone marrow, spleen, lymph nodes, 
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leukocytes, and thymus of mice and activated by medium chain fatty acids (Nagasaki 2012).  
GPR119 is highly expressed in the pancreatic islets and gastrointestinal tract of humans and has 
been suggested to be involved in glucose homeostasis (Kang 2013).  GPR120 has been shown to 
be activated by long chain fatty acids and is attracting attention as a potential target for type 2 
DM treatment (Milligan 2017). GPR120 knockout- mice subjected to high fat diets were found 
to develop obesity, glucose intolerance and exacerbated insulin resistance compared to wild type 
animals, suggesting its importance in metabolic functions (Alvarez 2016).  
As a trimer consisting of α, β, and γ subunits, G-proteins play a critical role in 
transducing signals from ligand-GPCR interactions and modulate downstream effector proteins.  
Upon ligand binding to the GPCR, the conformation of G-proteins changes to facilitate the 
binding of GTP by Gα, giving rise to a Gα-GTP monomer and a Gβγ dimer (Miller 2017). There 
are several different types of Gα such as Gαs, Gαi/o, Gαq/11, and Gα12/13 (Miller 2017). The 
activation of Gαs leads to increased levels of the second messenger cAMP (Miller 2017). cAMP 
modulates the activities of protein kinase A (PKA), a kinase which consists of two regulatory 
subunits and two catalytic subunits (Sassone-Corsi 2013).  Upon binding of cAMP to the 
regulatory subunits, these subunits dissociate from the catalytic subunits, thereby allowing the 
translocation and activation of PKA (Sassone-Corsi 2013). Activation of PKA leads to 
downstream activation of various transcription factors, including cyclic AMP responsive 
element- binding (CREB) protein (Alberts 2015) (Figure 1). Conversely, activation of Gαi 
signaling leads to the inhibition of adenylyl cyclase (Alberts 2015) (Figure 1). Finally, the 
activation of Gαq/11 leads to the activation of phospholipase C β, which in turn cleaves 
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol 
(DAG) (Alberts 2015). IP3 is required for the release of intracellular calcium, which is the 
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second messenger that activates PKC with DAG (Alberts 2015).  Activation of PKC leads to 
downstream activation of various transcription factors, Such as NF-κB (Kang 2014).   
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Figure 1: Downstream signaling of various heterotrimeric G proteins. (A) An example of Gαs 
signaling induced by binding of a ligand to the GPCR. (B) An example of Gαi signaling 
which leads to the inhibition of adenylyl cyclase. (C) An example of Gαq/11 signaling which 
leads to the release of intracellular calcium and the activation of PKC. (Alberts, 2015) 
Downstrea
m effects 
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There is evidence that ligand binding to GPR120 may recruit TAB-1 through the 
receptor-β-arrestin-2 complex, inhibiting the downstream activation of IKKs and JNKs, causing 
an anti-inflammatory state in the cell (Alvarez 2016).  CAAT/ enhancer binding protein β 
(C/EBPβ) has been shown to play a vital role in the transcriptional regulation of GPR120 (Chen 
et al 2016). GPR120 can also activate pathways through coupled G- heterotrimeric proteins such 
as αq/11, leading to the activation of phospholipase C (PLC) and downstream effectors, such as 
PKC (Chen 2012). Increased GLP-1 production due to GPR120 activation through this pathway 
is of interest for the treatment of DM (Liu 2015).  Previous studies have also shown short chain 
fatty acids bind to GPR41 and activate mitogen activated protein kinase (MAPK) via Gβγ-
mediated signaling (Inoue 2014). 
 The GLUT family of integral membrane proteins facilitate the transport of glucose and 
other sugars across the plasma membrane utilizing the diffusion gradients of these sugars (Wood 
2003). This family of facilitative transporters are divided into three classes based on their 
sequence similarity, with GLUT1-4 belonging to class I; GLUT5, GLUT7 and GLUT 9 
belonging to class II; and GLUT6, GLUT8, GLUT10, and GLUT12 belonging to class III (Wood 
2003). A key feature of class II facilitative transporters lies in their ability to transport fructose 
(Augustin 2010).  
 The expression of certain GLUT transporters has been shown to be regulated by various 
fatty acids. GLUT4 mRNA in 3T3-L1 adipocytes has been shown to be downregulated due to 
increased levels of the phospholipid ceramide (Long 1996). Similarly, exposure of H9C2 
cardiomyotubes to free fatty acids (Arachidonic, Stearic, Oleic and linoleic acids) has been 
reported to repress the promotor activity of GLUT4 (Armoni 2005).  GLUT 5 has been suggested 
to be the primary fructose transporter (Augustin 2017), and is shown to be expressed in the 
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jejunum region of the small intestines at a higher level, while in the kidney, brain, skeletal 
muscles and adipose tissue at a lower level (Corpe 2002). The primary function of GLUT5 has 
been described as mediating the uptake of fructose across the membrane of the small intestines, 
as it has a high affinity to fructose (Mueckler 2013).  In the gut, GLUT5 levels are regulated by 
the amount of fructose in the tissue (Jiang et al, 2001). Levels of fructose in individuals 
consuming diets high in fructose (as would be a risk factor for DM) can reach between 0.2-0.5 
mM (Douard 2008). Like the gut, GLUT5 mRNA levels in the brain are found to increase with 
increased fructose levels (Douard 2008). The physiological importance of GLUT5 in the brain is 
currently unknown. 
 The aim of this study is to understand how high levels of fatty acids effect the expression 
of various GPRs and GLUT transporters in neuronal cells. Specifically, GPR41, GPR84, 
GPR119, GPR120, GLUT3, GLUT5, GLUT6 and GLUT8 expression levels were investigated in 
Nuero2A (N2A) cells treated with palmitate. First, a dose response assay was conducted to 
determine the proper dose of palmitate for treatment purposes. A time course MTT assay was 
then performed to determine the optimal duration of treatment. N2A cells were then treated with 
palmitate or vehicle for 24 hours, and their RNA was isolated to determine the mRNA 
expression of these genes. N2A cells were also treated with GW9508, an agonist for GPR120 
and GPR40, and KT5720, a PKA inhibitor, to examine whether GPR120, GPR40, or PKA may 
potentially affect the expression of these genes.  
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Materials and methods 
Cell culture 
 Neuro-2A (N2A) cells were cultured in Eagles Modified essential Media (EMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% pennicellin/streptomyicin antibiotics. 
Cells were maintained at 37°C in a humidified incubator with 5% CO2.           
Cell viability/dose response assay 
N2A cells were seeded in 96 well plates in EMEM supplemented with 10% FBS and 1% 
penn/strep.  After a day, the media was changed to serum free EMEM and treated with either 
bovine serum albumin (BSA) or various concentrations of palmitate conjugated to BSA for 
specified periods of time.  Ten μL of 5 mg/ml MTT reagent was added to the cells and incubated 
for three hours. At the end of incubation, 100 μl of MTT stop solution was added to solubilize 
formanzan crystals. The plate was then read at 560nm using the Spectramax M5 plate reader. 
The absorbance values for each treatment group were normalized to the BSA control group and 
relative cell viability was calculated and graphed.  
RNA isolation  
   Total RNA was extracted from N2A cells using TRIzol (Sigma, St. Louis, MO) per 
manufacturer’s instructions. RNA quality was assessed by agarose gel electrophoresis and 
quantified by spectrophotometry. 
Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) 
cDNA was synthesized utilizing the following: 1 μg of total mRNA, 1 μL of 20μM 
OligodT, 5 μl of 5x Moloney murine leukemia virus (MMLV)- reverse transcriptase buffer, 1.25 
μl of 10 mM dNTP, 1 μL of reverse transcriptase, and nuclease-free water to bring the final 
volume to 25 μl.  Following reverse trancription, PCR was performed utilizing appropriate 
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primers for GPR41, GPR84, GPR119, GPR120, GLUT5, β-Actin and cyclophilin.  Each PCR 
reaction consisted of the following: 0.5 μl of forward primer (20 µM), 0.5 μl of reverse primer 
(20 µM), 18μl of Taq supermix and 1 μl of cDNA.  Five µl of each PCR reactions were then run 
on a 2% agarose gel, which was then imaged on the FlourChem E system (Protein Simple, San 
Jose, California).  The bands of interest were quantitated using alphaview software, and the data 
were normalized with house-keeping genes such as β-actin or cyclophilin.   
KT5720 and GW9508 treatment  
   N2A cells were seeded in 12 well plates in EMEM supplemented with 10% FBS and 1% 
pen/strep. Next day the complete media was replaced with EMEM and treated with 100 μM 
KT5720, an inhibitor for protein kinase A, 100μM GW9508, an agonist for GPR120 and GPR40, 
or vehicle for 24 hours.  Total RNA was then isolated from these cells as described previously.  
Statistical analysis 
All band intensities of RT-PCR were quantified using the alphaview software.  After 
normalization against actin or cyclophilin, the RT-PCR data from samples treated with vehicle or 
PA were analyzed by student’s t-test using the PRISM 6 software.  One-way ANOVA was used 
to analyze data from the PKA inhibitor and GPR120 agonist studies, and data from MTT assays. 
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Results  
Viability assay of cells treated with different concentrations of palmitate for 24 hours 
To determine the effects of palmitate on the viability of N2A cells, N2A cells were 
treated with 0, 25, 50, 100, 200, or 300 μM PA in unsupplemented EMEM for 24 hours or 48 
hours, and cell viability was analyzed by MTT assay. Analysis of the data revealed that treatment 
with palmitate decreased cell viability in a concentration-dependent manner such that when 
palmitate concentration increased, cell viability decreased (Figure 2). Specifically, 300 μM PA 
treatment decreased cell viability by well over 50% while 200 μM PA treatment decreased cell 
viability by about 50%. 100 μM PA treatment decreased cell viability relatively less than 200μM 
PA treatment, while 25 μM and 50 μM PA treatment did not have noticeable impact on the 
viability of N2A cells.   
Following treatment for 48 hours, both 200 μM and 300 μM PA treatment significantly 
reduced N2A cell viability by over 50%.  100 μM PA treatment reduced cell viability by nearly 
50%, while 25 μM and 50 μM PA treatment did not have a noticeable effect on the viability of 
the cells relative to vehicle (Figure 3). 
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Figure 2: Viability of N2A cells treated with various concentrations of palmitate or BSA for 24 
hours as measured with MTT assay. Data shown as mean ± SD. N=3.  
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Figure 3: Viability of N2A cells treated with varying concentrations of palmitate or BSA for 48 
hours as measured with MTT assay.  Data shown as mean ± SD. N=3.  
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Viability of N2A cells treated with 300μM palmitate for different periods of time 
 
 To determine the optimal time for treatment, N2A cells were treated with 300 μM PA for 
6, 24 and 48 hour, and cell viability was analyzed with MTT assay. Analysis of the data reveals 
that treatment with palmitate decreased cell viability in a time-dependent manner (Figure 4). Cell 
viability after 48 hour treatment with PA decreased over 50%, while 24 hour treatment showed 
about 50% decrease in viability, while treatment with PA for 6 hours did not significantly change 
cell viability compared to BSA.   
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Figure 4: Viability of N2A cells treated with 300μM palmitate for 6, 24 and 48 hours as 
measured with MTT assay.  Data shown as mean ± SD. N=3.  
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Effect of PA treatment on the mRNA expression of GPR41 and GPR84 
 GPR41 is a G-protein coupled receptor (GPCR) for short chain fatty acids, and may be 
involved in energy metabolism.  GPR84 is a receptor for medium chain fatty acids, and may be 
involved in energy metabolism and immune response.  To determine how palmitate affected the 
mRNA expression of GPR41 and GPR84, N2A cells seeded in 12 well plates were treated with 
300 µM palmitate or vehicle for 24 hours. RNA was isolated from these cells using TRIzol. RT-
PCR reactions using primers specific for GPR41 and GPR84 were performed and run on 2% 
agarose gel.  The gel was imaged and gene-specific bands were quantified with alphaview 
software, and normalized against actin.  As shown in Figure 5, treatment with 300 μM palmitate 
significantly increased the mRNA expression of GPR41 and GPR84 (Figure 5).   
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Figure 5: mRNA expression of GPR41 and GPR84 in N2A cells at 24 hours following treatment 
with BSA or 300 µM PA as measured by semi-quantitative RT-PCR. (A) RT-PCR result of 
GPR41 expression when treated with 300μΜ of palmitate or vehicle. (B) Relative mRNA 
expression of GPR41 as normalized against β-actin. Data shown as mean ± SD. N=3. (C) RT-
PCR result of GPR84 expression when treated with 300μΜ of palmitate or vehicle. (D) Relative 
mRNA expression of GPR84 as normalized against β-actin. Data shown as mean ± SD. N=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
D. C. 
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Effect of PA treatment on medium chain fatty acid receptor GPR119 and GPR120 expression  
 
 GPR119 has been suggested as a receptor for fatty acid amides and monoacylglycerol 
and a potential target for the treatment of type 2 DM.  GPR120 is a receptor for medium and long 
chain fatty acids.  It has also been shown to bind to ω-3 unsaturated fatty acids and a potential 
target for the treatment of type 2 DM.  The effects of palimitate on the mRNA expression of 
these two receptors were thereby determined.  Gel electrophoresis depicted GPR119 band 
intensity higher for the cells treated with 300μM palmitate than those treated with 300μM 
vehicle (Figure 6).  The mRNA expression of GPR119 and GPR120 was significantly increased 
in cells following 24 hour-treatment with 300 µM PA as compared to the cells treated with BSA 
(Figure 6).   
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Figure 6: mRNA expression of GPR119 and GPR120 in N2A cells at 24 hours following 
treatment with BSA or 300 µM PA as measured by semi-quantitative RT-PCR (A) RT-PCR 
result of GPR119 gene expression when treated with 300μΜ of palmitate or vehicle. (B) Relative 
mRNA expression of GPR119 as normalized against β-actin. Data shown as mean ± SD. N=3. 
(C) RT-PCR result of GPR120 expression when treated with 300μΜ of palmitate or vehicle. (D) 
Relative mRNA expression of GPR120 as normalized against β-actin. Data shown as mean ± 
SD. N=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
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Effect of PA treatment on the mRNA expression of class I and class III GLUT transporters  
 
 GLUT3 is a class I transporters that has been found to transport glucose.  GLUT6 and 
GLUT8 are class III transporters that have been reported to transport glucose.  To examine 
whether treatment with palmitate affected the expression of these glucose transporters, N2A cells 
were treated with 300 µM palmtate or BSA for 24 hours, and RT-PCR was conducted to 
examine the mRNA expression level of these genes.  The mRNA expression of GLUT3, GLUT6 
or GLUT8 genes was comparable in cells treated with palmitate and those cells treated with 
vehicle (Figure 7).  
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Figure 7: mRNA expression of GLUT3, GLUT6 and GLUT8 genes in N2A cells at 24 hours 
following treatment with BSA or 300 µM PA as measured by semi-quantitative RT-PCR. (A) 
RT-PCR result of GLUT3, GLUT6 and GLUT8 gene expression when treated with 300μΜ of 
palmitate or vehicle. (B) Quantification of GLUT3 PCR bands as normalized against β-actin. 
Data shown as mean ± SD. (C) Quantification of GLUT6 PCR bands as normalized against β-
actin. Data shown as mean ± SD. (D) Quantification of GLUT8 PCR bands as normalized 
against β-actin. Data shown as mean ± SD. 
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Effect of PA treatment on the mRNA expression of GLUT5 
 
 GLUT5 is a class II glucose transporter and has been found to transport fructose.  To 
determine how palmitate treatment affected the mRNA expression of GLUT5, N2A cells were 
treated with palmitate or BSA for 24 hours, and the mRNA expression level of GLUT5 gene was 
examined using RT-PCR.  As shown in Figure 8, the mRNA expression of GLUT5 gene was 
significantly higher cells treated with 300μM palmitate than those treated with BSA vehicle.   
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Figure 8: mRNA expression of GLUT5 in N2A cells at 24 hours following treatment with BSA 
or 300 µM PA as measured by semi-quantitative RT-PCR. (A) RT-PCR result of GLUT5 
expression when treated with 300μΜ of palmitate or vehicle. (B) Relative mRNA expression of 
GLUT5 as normalized against β-actin. Data shown as mean ± SD. N=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
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Effects of KT5720 and GW9508 on the mRNA expression of GPRs 
 KT5720 is an inhibitor of PKA.  GW9508 is an agonist for GPR40 at lower concentration 
and GPR120 at higher concentration.  In order to examine whether GPR signaling pathway was 
involved in palmitate induced changes in the mRNA expression of GPRs, N2A cells were treated 
100 µM KT5720, 100 µM GW9508, 300 µM PA, and BSA for 24 hours, RNA was isolated, and 
RT-PCR was conducted with primers specific for GPR41, GPR119, and GPR120 respectively.  
Treatment with 300μM palmitate increased the mRNA expression levels of GPR41, GPR119 and 
GPR120 mRNA expression relative to the control (α < 0.05, Figure 9).  The mRNA expression 
levels of GPR41 and GPR119 were higher in the cells treated with 100 μM KT5720 as compared 
to those treated with BSA alone while the mRNA level of GPR120 was not significantly altered 
by the treatment with 100μM KT5720 (Figure 9).  Treatment with 100 μM GW9508 did not 
significantly change the mRNA expression for GPR41 or GPR119 as compared to the BSA 
control.  However, treatment with 100 μM GW9508 did increase the mRNA expression level of 
GPR120 gene as compared to the control (Figure 9C and 9F).  
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Figure 9: mRNA expression of GPR41, GPR119 and GPR120 in N2A cells at 24 hours 
following treatment with BSA, 100μM of KT5720, 100μM of GW9508, or 300 µM PA as 
measured by semi-quantitative RT-PCR. (A, B and C) RT-PCR result of GPR41, GPR119 and 
GPR120 expression when treated with 300μΜ of vehicle, 100μM of KT5720, 100μM of 
GW9508, or 300μM of palmitate. (D, E and F) Quantification of PCR bands as normalized to β-
actin. Data shown as mean ± SD. N=3. 
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Effects of treatment with KT5720 and GW9508 on the mRNA expression of GLUT5 
 In order to examine whether GPR signaling pathway was involved in palmitate induced 
changes in the mRNA expression of GLUT5, N2A cells were treated with 100 μM KT5720, 100 
μM GW9508, 300 μM PA, or BSA for 24 hours.  RT-PCR with primers specific for GLUT5 was 
performed.  The mRNA level of GLUT5 gene was higher in cells treated with 300μM palmitate 
and cells treated with 100uM KT5720 as compared to those treated with BSA alone (Figure 10). 
Treatment with 100 μM GW9508 did not induce significant changes in mRNA expression for 
GLUT5 gene (Figure 10).  
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Figure 10: mRNA expression of GLUT5 in N2A cells at 24 hours following treatment with 
BSA, 100μM of KT5720, 100μM of GW9508, or 300 µM PA as measured by semi-quantitative 
RT-PCR. (A) RT-PCR result of GLUT5 expression when treated with BSA, 100μM of KT5720, 
100μM of GW9508, or 300μM of palmitate. (B) Quantification of PCR bands normalized to β-
actin. Data shown as mean ± SD. N=3. 
 
 
 
 
 
 
 
 
 
 
A. 
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Discussion 
 This study examined the effects of palmitate on the mRNA expression of select GPCRs 
and GLUT transporters in neuronal cells. Palmitate is the most abundant saturated free fatty acid 
in plasma, constituting up to 30% of total FFAs in the serum (Weigert 2004). Furthermore, the 
concentration of FFAs can rise to over 1 mM following a fatty meal, as would be expected with 
individuals with metabolic disorders (Weigert 2004). The results of the viability assay pertaining 
to the varying palmitate concentrations at 24 or 48 hours revealed that the highest dose of 
palmitate (300 μM) produced the greatest difference in viability when compared to vehicle 
(Figures 2 and 3). Therefore, the 300 μM dosage of palmitate was used for treatment. To 
determine the time-point to use for palmitate treatment, an MTT assay was performed using the 
6, 24 and 48 time points with the 300 μM palmitate. The results of this assay showed that 48 
hours of treatment with 300 μM palmitate caused a severe reduction in cell viability compared to 
BSA control. Treatment with 300 μM palmitate for 6 hours did not significantly influence cell 
viability, while 24 hour treatment decreased cell viability by about 50% (Figure 4). Therefore, 
for the purpose of the gene expression studies, the 24 hour time point treatment with 300 µM PA 
was used for physiological relevance. 
The effects of palmitate treatment on the mRNA expression of GPRs were examined in 
this study. GPRs have been of interest for the study of fatty acids due to their roles in regulating 
metabolic and immune processes (Alvarez 2016). Increased GPR120 mRNA may be attributed 
to C/EBPβ activation (Chen 2012). C/EBPβ has been shown to play a vital role in the 
transcriptional regulation of GPR120 and its role in N2A cells treated with palmitate is currently 
unknown (Chen et al 2016). GPR119 is of interest in the study of fatty acids due to the release of 
glucagon like peptide-1 (GLP-1) upon stimulation of the receptor (Hansen 2012). The regulation 
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behind GPR119 expression, however, is not yet so clear. GPR41 (FFAR3) is unique in that it’s 
transcribed as a bicistronic mRNA, with GPR40 upstream of it (Halpbern et al 2012). The HR2 
enhancer is important for the expression of this bicistronic mRNA (Halpbern et al 2012). Within 
the regulatory sequences of HR2 lie consensus sites for the signal transducer and activator of 
repression (STAT) family of transcription factors, pancreatic duodenal homeobox-1 (PDX-1) 
and BETA2 transcription factors (Ridner 2008). This receptor is known to be activated by short 
chain fatty acids and upon activation, it is known that this receptor plays a role in mediating anti-
inflammatory effects (Alvarez 2016). GPR84 is a medium chain fatty acid receptor that has been 
suggested to be regulated by the transcription factor NF-κB (Nagasaki 2012).  
 Treatment with palmitate for 24 hours upregulated the mRNA levels of GPR41, GPR84, 
GPR120, and GPR119 (Figures 5 and 6). The responsive increase in short, medium and long 
chain fatty acid receptor mRNA expression in response to palmitate treatment may be explained 
through the activation of various signaling pathways, include protein kinase C (PKC) and 
glycogen synthase kinase 3β (GSK3). Downstream signaling from PKC has been shown to lead 
to the activation of NF-κB (Kang 2014). Glycogen synthase kinase 3β directly activates C/EBPβ 
through phosphorylation (Chen 2012). Thus, it seems as if palmitate- induced activation of these 
two pathways may help to explain the observed increase in the mRNA expression of GPR 84 and 
GPR120. This palmitate-induced activation may occur through GPR120 or GPR40 stimulation. 
Further promotor studies are required to understand the cause of both GPR41 and GPR119 
increased mRNA expression.    
 GLUT1, GLUT4 and GLUT5 have been found to be important for the transport of sugars 
in white adipose tissue and the overall function of WAT (Wood 2003). The enlargement of 
adipocytes and increased fasting level of FFAs has been reported in obese individuals 
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(Greenberg 2006).  In Caco-2 cells, the glucocorticoid receptor is thought to play a role in 
regulating the expression of GLUT5 (Takabe 2008).  Whether this receptor is involved in the 
observed effects by palmitate in N2a cells remains unknown.  However, fructose concentrations 
have also been shown to regulate GLUT5 expression (Douard 2008).  Many studies have shown 
a correlation between increased fructose consumption and increased incidence of type 2 diabetes 
and obesity (Douard 2008). Typically the brain is dependent on glucose as its main energy 
source (Maher 1991). However, recent studies suggest that the polyol pathway contributes to the 
production of fructose in the CNS (Hwang 2017). While the mRNA expression of GLUT3, 
GLUT6, and GLUT8 genes was not significantly altered by the treatment with 300 µM PA, the 
mRNA expression of GLUT5 was significantly upregulated by treatment with 300 µM PA for 24 
hours (Figures 7 and 8). Other studies of different GLUT genes have shown that fatty acid 
treatment decreases the mRNA levels of GLUTs (Long 1996). The observed increase in mRNA 
level of GLUT5 in response to palmitate treatment warrants investigating the role of fructose in 
neuronal cell metabolism. Further testing at lower PA concentrations is also needed to attenuate 
any variability resulting from apoptotic events.   
 The use of KT5720 to inhibit PKA and elucidate its role in response to a stimuli is well 
documented (Batty 2017). In this study, N2A cells were treated with vehicle or 100 μM of 
KT5720 to determine whether it is likely for PKA to be involved in palmitate treatment induced 
changes.  Treatment with 100 μM KT5720 increased the mRNA expression of GLUT5 as did the 
treatment with palmitate (Figure 10).  Similarly, the mRNA expression of GPR41 and GPR119 
was upregulated by the treatment with KT5720 as well as the palmitate (Figure 9).  These data 
suggest that PKA-mediated signaling may negatively regulate the mRNA expression of GLUT5, 
GPR41 and GPR119. Interestingly, other studies have found that inhibiting PKA in neonatal rats 
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in a fructose-induced state with PKA inhibitor or H89 did not affect GLUT5 mRNA level in the 
small intestine (Cui 2004). Whether PKA might play a role in palmitate induced changes in the 
mRNA expression of GLUT5, GPR41, and GPR119 in neuronal cells needs further 
investigation.  
 GW9508 acts as an agonist to both GPR40 and GPR120 with 100 fold lower binding 
affinity for GPR120 than for GPR40 (Briscoe 2003; Milligram 2017). Activation of GPR120 
through Gα leads to the coupling of the Gαq
 to phospholipase C (PLC) (Liu 2015). Downstream 
signaling from PLC leads to increased diacylglycerol (DAG) and calcium concentrations, 
activating PKC and further downstream transcription factors (Liu 2015).  Similarly, GPR40 
activation from fatty acid binding leads to increased DAG and calcium concentrations through 
Gαq/11 signaling (Burant 2013). However, activation of GPR120 via phosphorylation of its C-
terminus promotes a recruitment of TAB1, a protein which disrupts the TAK1/TAB2/3 complex 
and consequently inhibits IKK and JNK signaling (Liu 2015). Activation of GPR40 has also 
been shown to increase phosphorylation of cyclic amp responsive binding element (CREB) and 
ERK 1/2 (Miyamoto 2016). Clarifying which pathway is activated in response to stimulation 
with GW9508 is still required.  It also remains unclear whether GW9508 treatment activates both 
pathways in the neuronal cells and what the net effects are.  Also, it remains to be determined 
whether unsaturated and saturated fatty acids induce an additive, synergistic, or antagonizing 
effects in neuronal cells.  
 Overall, this study examined the effects of palmitate treatment on the mRNA expression 
of GPRs and GLUTs in N2A cells.  Further investigation may be conducted to better understand 
the mechanisms of palmitate-induced effects in N2A cells.   These studies may shed light on how 
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increased levels of palmitate may contribute to the development of diabetes and diabetes-
associated neuropathy.   
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